>>What is your estimate of the probability-weighted buyout price and premium in the LEVP deal?
Lot of guess work to answer that one.
CVR1 - attaining $600M in rev.
CVR2 - orphan for acute or 2 years without competition. (Chances improved as it seems that CSL has fallen behind VPHM which now has a 6/3 PDUFA for acute.)
Probability / value ps
CVR1 - 90% / $0.45
CVR2 - 60% / $0.30
ij
There are times when rules and precedents cannot be broken; others when they cannot be adhered to with safety. (Thomas Joplin)